News
Media Coverage
-
- 25
- 2022/08
People Daily Health｜Sino Biopharm Releases Semi-annual Report, Aims at 100 Billion Revenue in 2030
"The company will achieve its strategic goal of HK$100 billion revenue by 2030 through comprehensive innovation and transformation driven by independent research and development and external introduction. 79 products are expected to be launched in the next three years," said Miss Tse, Theresa Y Y, Chairwoman of the Board of Directors of Sino Biopharm.View > -
- 25
- 2022/08
Takungpao｜Sino Biopharm's New CEO Makes his Debut and Promotes Operational Reform
Hang Seng Index constituent Sino Biopharm (HK0.1177) held its first half-year results conference and the first investor day in Beijing on August 24th, where the new CEO Mr. Tse, Eric S Y made his debut.View > -
- 24
- 2022/08
Xinhua News Agency｜Sino Biopharm's First-half Year Revenue Reaches 15.19 billion RMB
Beijing, Aug. 24 (Xinhua News Agency, reported by Xia Ke) - Sino Biopharmaceutical Limited (hereinafter referred to as Sino Biopharm) held a first-half results conference in Beijing on the 24th. Its semi-annual results show that the first half-year operating revenue of Sino Biopharm reached 15.19 billion RMB, an increase of 5.9% year-on-year. Chairwoman of the Board of Directors of Sino Biopharm, Miss Tse, Theresa Y Y,View > -
- 23
- 2022/08
China Securities Journal｜Sino Biopharm: First-half Year Revenue Reaches 15.19 Billion yuan and Innovative Drug Revenue May Exceed 10 billion yuan Next Year
(China Securities Journal Report by Fu Suying) On August 23, Sino Biopharm released its 2022 half-year performance report. In the first half of this year, the company's revenue was 15.19 billion yuan, an increase of 5.9% year-on-year; excluding the share of earnings of associates/joint ventures and the effect of adjustment of non-recurring gains and losses, the net profit attributable to the mother company reached 1.66 billion yuan, an increase of 4.5%.View > -
- 23
- 2022/08
China Economic Net｜Hedging the Impact of Centralized Procurement, Sino Biopharm's New Products Listed in the Past 5 Years Generated 40% of Revenue
Under the influence of the normalization of the centralized procurement, focusing on innovative research and development has become the only path for pharmaceutical companies to break out of the circle. Hong Kong Hang Seng Index stock company Sino Biopharm (HK.01177) released its 2022 interim results report on August 23, showing that new products, innovative drugs and oncology drugs have become the company's second growth curve,View > -
- 17
- 2022/06
Takungpao｜Sino Biopharm 2021 ESG Report: Solidifying the Foundation of ESG Governance and Focusing on Diversifying Talent Cultivation
The performance of ESG management has become an important factor in measuring the sustainability of listed companies, and ESG reports are receiving increasing attention as an important way to systematically explain the ESG management of companies. Recently, Sino Biopharm (HK.1177) released its ESG report for the sixth consecutive year, specifically specifying the key development direction of strengthening the construction of "Responsible Sino Biopharm".View > -
- 09
- 2022/03
CHINADAILY｜Sino Biopharm announces clinical trials for pneumoconiosis drug
Sino Biopharmaceutical Limited, or Sino Biopharm, a leading innovative research and development-driven pharmaceutical conglomerate in China, announced on Tuesday that TDI01 suspension, an innovative drug independently developed by its subsidiary Beijing Tide Pharmaceutical Co Ltd, had received approval from the National Medical Products Administration for clinical trials on treating pneumoconiosis, a key occupational disease in China that affects the lungs and is caused by inhalation of dust.View > -
- 21
- 2021/05
“Aprepitant Capsules” obtains Drug Registration Certificate
Recently, “Aprepitant Capsules” (brand name: “Shanyi” (善依)) (approved specifications: 80mg and 125mg), an adjuvant drug for tumor treatment developed by the Group, has obtained the drug registration certificate from the National Medical Products Administration of the People’s Republic of China.View > -
- 13
- 2021/05
“Dasatinib Tablet” Passes Consistency Evaluation
Recently, “Dasatinib Tablet” (product name: Yinishu) (specifications: 20mg and 50mg), an oncology medicine developed by the Group, has obtained the notice of approval of supplemental application on pharmaceutical product issued by the National Medical Products Administration of the People’s Republic of China,View > -
- 13
- 2021/05
“Palonosetron Hydrochloride Injection” Passes Consistency Evaluation
Recently, “Palonosetron Hydrochloride Injection” (Product name “Zhiruo”) (specifications: 5ml: 0.25mg and 1.5ml: 0.075mg), a drug developed by the Group, for the prevention of nausea and vomiting caused by chemotherapy has obtained the notice of approval of supplemental application on pharmaceutical product issued by the National Medical Products Administration of the People’s Republic of China, and passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs.View >